With Novartis' Kisqali, Pfizer faces its first in-class threat for Ibrance

14th March 2017 Uncategorised 0

With Novartis’ Kisqali, Pfizer faces its first in-class threat for Ibrance
chelfand
Tue, 03/14/2017 – 11:17




More: With Novartis' Kisqali, Pfizer faces its first in-class threat for Ibrance
Source: fierce